Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection

Journal of the American Geriatrics Society

Volumn 62, Issue 3, 2014, Pages 447-453

  Greene, Meredith ^a,b   Steinman, Michael A ^a,b   McNicholl, Ian R ^c   Valcour, Victor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

drug interactions; HIV infection; inappropriate prescribing; polypharmacy

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ATAZANAVIR; ATORVASTATIN; CALCIUM CARBONATE; CETIRIZINE; CITRATE CALCIUM; EFAVIRENZ; EMTRICITABINE; IBUPROFEN; LORAZEPAM; MULTIVITAMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; RITONAVIR; TENOFOVIR; ZOLPIDEM;

ADULT; AGED; ANTICHOLINERGIC EFFECT; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; FEMALE; GERIATRIC CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYPHARMACY; REVIEW;

DRUG INTERACTIONS; HIV INFECTION; INAPPROPRIATE PRESCRIBING; POLYPHARMACY;

AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; HIV; HIV INFECTIONS; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MEDICATION ERRORS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; RETROSPECTIVE STUDIES;

EID: 84896398864     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12695     Document Type: Review

References (35)

1. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project. Treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc 2012; 60: 974-979.
2. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622.
3. Crothers K, Butt AA, Gibert CL, et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006; 130: 1326-1333.
4. Brown TT, Qaqish RB,. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 2006; 20: 2165-2174.
5. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol 2011; 17: 3-16.
6. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: The Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63: 822-827.
7. Desquilbet L, Margolick JB, Fried LP, et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr 2009; 50: 299-306.
8. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One 2013; 8: e54910.
9. Morgan EE, Iudicello JE, Weber E, et al. Synergistic effects of HIV infection and older age on daily functioning. J Acquir Immune Defic Syndr 2012; 61: 341-348.
10. Steinman MA, Hanlon JT,. Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA 2010; 304: 1592-1601.
11. Krentz HB, Cosman I, Lee K, et al. Pill burden in HIV infection: 20 years of experience. Antivir Ther 2012; 17: 833-840.
12. Furler MD, Einarson TR, Walmsley S, et al. Polypharmacy in HIV: Impact of data source and gender on reported drug utilization. AIDS Patient Care STDs 2004; 18: 568-586.
13. Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15: 413-423.
14. Marzolini C, Back D, Weber R, et al. Ageing with HIV: Medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 2107-2111.
15. Yiu P, Nguyen NN, Holodniy M,. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacotherapy 2011; 31: 480-489.
16. Darque A, Enel P, Ravaux I, et al. Drug interactions in elderly individuals with the human immunodeficiency virus. J Amer Geriatr Soc 2012; 60: 382-384.
17. Jahanshad N, Valcour VG, Nir TM, et al. Disrupted brain networks in the aging HIV+ population. Brain Connect 2012; 2: 335-344.
18. Hajjar ER, Cafiero AC, Hanlon JT,. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5: 345-351.
19. Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200-209.
20. Lexi-Comp, Inc. Lexicomp Lexi-Interact Online, Hudson, OH: Lexi-Comp, Inc., 2013.
21. Micromedex 2.0. Greenwood Village, CO: Truven Health Analytics [on-line]. Available at http://www.micromedexsolutions.com/home/dispatch Accessed December 17, 2012.
22. McEvoy GK, Snow ED, eds. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 2012.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [on-line]. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf Section Accessed December 17, 2012.
24. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Amer Geriatr Soc 2012; 60: 616-631.
25. Crum NF, Furtek KJ, Olson PE, et al. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: Diagnosis, pathogenesis, and management. AIDS Patient Care STDs 2005; 19: 655-671.
26. Karimi S, Dharia SP, Flora DS, et al. Anticholinergic burden: Clinical implications for seniors and strategies for clinicians. Consult Pharm 2012; 27: 564-582.
27. Rudolph JL, Salow MJ, Angelini MC, et al. The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-513.
28. Mateen FJ, Shinohara RT, Carone M, et al. Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. Neurology 2012; 79: 1873-1880.
29. Dhalla S, Chan KJ, Montaner JS, et al. Complementary and alternative medicine use in British Columbia-a survey of HIV positive people on antiretroviral therapy. Complement Ther Clin Pract 2006; 12: 242-248.
30. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300: 2867-2878.
31. Centers for Disease Control and Prevention. Diagnoses of HIV infection among adults aged 50 years and older in the United States and dependent areas, 2007-2010. HIV Surveillance Supplemental Report 2013;18(No. 3) [on-line]. Available at http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ #supplemental Accessed August 4, 2013.
32. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 U.S. dependent areas-2010. HIV Surveillance Supplemental Report 2013;18(No. 2, part B) [on-line]. Available at http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/#supplemental Accessed August 6, 2013.
33. O'Keefe KJ, Scheer S, Chen MJ, et al. People fifty years or older now account for the majority of AIDS cases in San Francisco, California, 2010. AIDS Care 2013; 25: 1145-1148.
34. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002; 287: 337-344.
35. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: Findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001; 286: 2823-2829.